Skip to main content
. Author manuscript; available in PMC: 2013 Jun 17.
Published in final edited form as: Leukemia. 2009 Aug 6;23(10):1913–1919. doi: 10.1038/leu.2009.129

Figure 3.

Figure 3

Overall survival (OS) and Event-free survival (EFS) for both actual and predicted bone disease (Total Therapy 2 (TT2) model). (a) OS is shown for patients with known limited and extensive bone disease and compared with the survival for patients predicted by the four single nucleotide polymorphism (SNP) model to have limited and extensive disease. The listed P-values indicate that OS is statistically inferior for patients with both actual and predicted extensive versus limited bone disease (P = 0.0183). The actual versus predicted outcomes are not different (P-values 0.693 and 0.881, respectively). (b) EFS is shown for patients with known limited and extensive bone disease and compared with EFS for patients predicted to have limited and extensive bone disease based on the four SNP model (Figure 1). The P-values indicate that EFS is not different for limited versus extensive disease, but this is true for both the actual and predicted patient populations (P-values: overall 0.185; and 0.327 and 0.924 for comparisons).